NEW YORK, April 25, 2013 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, such as primary biliary cirrhosis, today announced that Mark Pruzanski, MD, President and Chief Executive Officer, will present at the following investor conferences in May:
- Needham 2013 Healthcare Conference on May 1, at 10:40 a.m. Eastern Time at the Westin Grand Central Hotel in New York City
- Bank of America 2013 Health Care Conference on May 15, at 1:40 p.m. Pacific Time at the Encore at the Wynn in Las Vegas
Live and archived audio webcasts of the company's sessions will be available on the "Events" section of Intercept's investor website at http://ir.interceptpharma.com.
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver diseases, such as primary biliary cirrhosis, utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA) is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC) in patients with an inadequate response to, or who are unable to tolerate, ursodiol, the only approved therapy for this indication. OCA has received orphan drug designation in both the United States and Europe for the treatment of PBC. Intercept owns worldwide rights to OCA outside of Japan and China, where it has out-licensed the product candidate to DSP. For more information about Intercept, please visit the Company's website at:www.interceptpharma.com.
For more information about Intercept, please contact Mark Pruzanski, M.D., or Barbara Duncan, both of Intercept Pharmaceuticals, at 1-646-747-1000.
CONTACT: Intercept Pharmaceuticals 1-646-747-1000Source:Intercept Pharmaceuticals, Inc.